Provention Bio, Inc.
PRVB · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 824.4% | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 96% | 100% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -967% | -8,257.4% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -880.7% | -8,203% | – | – |
| EPS Diluted | -1.52 | -1.81 | -1.88 | -1.04 |
| % Growth | 16% | 3.7% | -80.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |